AstraZeneca’s Imfinzi plus chemotherapy doubled overall survival rate for patients with advanced biliary tract cancer
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Longest survival follow-up ever reported for immunotherapy treatment in this setting
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
The company will respond to the Warning Letter within the stipulated timelines
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
New leadership team announced at NATHEALTH Annual General Meeting 2024
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Subscribe To Our Newsletter & Stay Updated